Teva extends revolving credit facility maturity to April 2028, adjusts leverage covenants

TEVA PHARMACEUTICAL INDUSTRIES LTD

Maturity extended from April 2027 to April 2028 via second one-year extension of the revolving facility.
Maximum leverage ratio set at 4.25x for Q4 2025 and thereafter; can increase 0.5x for acquisitions over $250M.
Covenants suspended if Teva achieves Investment Grade Status (Baa3/BBB- from two agencies); reinstated on loss or default.
Consent fee of 0.08% of total commitments paid to lenders approving the amendment.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

TEVA PHARMACEUTICAL INDUSTRIES LTD amended Third Amendment to the Senior Unsecured Sustainability-Linked Revolving Credit Agreement with the Lenders party to its Revolving Facility Agreement and Bank of America, N.A., as administrative agent (effective 2025-12-10).

Action: amendment
Agreement: credit facility
Counterparty: the Lenders party to its Revolving Facility Agreement and Bank of America, N.A., as administrative agent
Effective: 2025-12-10

Exact text from the filing

On December 10, 2025, Teva Pharmaceutical Industries Limited (the “Company”) obtained the consent of each of the lenders (the “Lenders”) party to its Revolving Facility Agreement (as defined below) to extend the stated maturity date of the commitments and loans thereunder from April 29, 2027 to April 29, 2028, and to amend certain terms of the financial covenants contained in the Revolving Facility Agreement pursuant to the Third Amendment to the Senior Unsecured Sustainability-Linked Revolving Credit Agreement (the “Amendment”).

View on SEC.gov

Browse all material agreements →

TEVA PHARMACEUTICAL INDUSTRIES LTD filing history →

Source: SEC EDGAR

accession 0001193125-25-316063

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.